Australia markets closed

STOK Nov 2024 20.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.50000.0000 (0.00%)
At close: 09:30AM EDT
Full screen
Previous close2.5000
Open2.5000
Bid1.6000
Ask3.3000
Strike20.00
Expiry date2024-11-15
Day's range2.5000 - 2.5000
Contract rangeN/A
Volume1
Open interest73
  • Business Wire

    Stoke Therapeutics to Present at Upcoming Investor Conferences in June

    BEDFORD, Mass., June 03, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:

  • GuruFocus.com

    Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

    On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:STOK), executed a significant stock transaction, selling 42,350 shares of the company.

  • Business Wire

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    BEDFORD, Mass., May 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing